TUDCA in High-Risk Lactating Mothers Identified by Early Postpartum Milk Hydrophobicity Index

Inclusion Criteria: * Lactating mother aged 18 to 45 years * Within 72 hours after delivery at screening * Intention to continue breastfeeding or providing expressed breast milk during the treatment period * Maternal metabolic dysfunction-associated steatotic liver disease (MASLD) defined by protocol-specified clinical criteria * Early postpartum breast milk sample meeting the predefined high-risk bile acid hydrophobicity index threshold * Live-born infant considered clinically stable and eligible for enteral feeding * Ability and willingness to provide written informed consent for maternal participation and infant-related study procedures Exclusion Criteria: * Maternal chronic liver disease other than MASLD, decompensated liver disease, biliary obstruction, acute cholecystitis, or pancreatitis * Current use of ursodeoxycholic acid, tauroursodeoxycholic acid, or another protocol-prohibited bile acid-modifying medication * Maternal severe renal insufficiency or other clinically significant condition judged by the investigator to increase study risk * Preterm infant less than 37 weeks of gestation or birth weight less than 2500 g * Major congenital anomaly or infant condition requiring ongoing intensive care at enrollment * Any condition that, in the investigator's judgment, makes the mother-infant dyad unsuitable for participation